<DOC>
	<DOC>NCT00359762</DOC>
	<brief_summary>This study assesses the effects of twice-daily subcutaneous injection exenatide versus treatment with sulfonylurea (glimepiride) on long-term glycemic control and beta-cell function.</brief_summary>
	<brief_title>Exenatide Versus Glimepiride in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosed with type 2 diabetes mellitus. Treated with diet and exercise and a stable, maximally tolerated dose of metformin for at least 3 months prior to screening. HbA1c &gt;=6.5% and &lt;=9.0%. Body Mass Index (BMI) &gt;=25 kg/m^2 and &lt;40 kg/m^2. Participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to screening. Characteristics contraindicating metformin or glimepiride use. Receiving drugs that directly affect gastrointestinal motility. Receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy. Have used any prescription drug to promote weight loss within 3 months prior to screening. Treated for longer than 2 weeks with any of the following medications within 3 months prior to screening: *insulin; *thiazolidinediones; *alphaglucosidase inhibitors; *sulfonylurea; *meglitinides</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>glimepiride</keyword>
</DOC>